Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 37: 2081-2086, 1991;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tachikawa, T.
Right arrow Articles by Yanaihara, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tachikawa, T.
Right arrow Articles by Yanaihara, N.

Clinical Chemistry, Vol 37, 2081-2086, Copyright © 1991 by American Association for Clinical Chemistry

Novel method for quantifying alpha(1----3)-L-fucosyltransferase activity in serum

T Tachikawa, S Yazawa, T Asao, S Shin and N Yanaihara
Diagnostic Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.

A novel method has been developed to quantify alpha(1----3)-L- fucosyltransferase activity in human sera by applying a sandwich-type immunoradiometric assay. H type 2 trisaccharide (6Fuc alpha 1----2Gal beta 1----4GlcNAc) covalently attached to bovine serum albumin (BSA) was used as an acceptor and incubated with serum samples in the presence of guanosine diphosphate-fucose. The resulting product, Y tetrasaccharide (Fuc alpha 1----2Gal beta 1----4[Fuc alpha 1----3] GlcNAc beta-BSA), was detected by a sequential use of anti-BSA antibody- coated bead and 125I-labeled anti-Y antibody. Inter- and intra-assay CVs for alpha(1----3)-L-fucosyltransferase were both less than 4%, and the results of the dilution linearity and analytical recovery studies were satisfactory. Using the present assay method, we measured alpha(1-- --3)-L-fucosyltransferase in serum from patients with benign and malignant gastric disorders and in healthy subjects. The detection rate of alpha(1----3)-L-fucosyltransferase for cancer was apparently higher than that of carcinoembryonic antigen measured in the same samples, particularly in the early clinical stage; indeed, no correlation was observed between the concentrations of the two potential markers. The results indicate that the present assay method seems to be excellent for the determination of serum alpha(1----3)-L-fucosyltransferase activity and useful for the detection of cancer-associated increases of the enzyme activity at the early stage of gastric cancer.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American Association for Clinical Chemistry.